Introduction {#S1}
============

Pediatric solid organ transplantation has transformed the survival rate and quality of life for patients with organ dysfunction and failure. In the last 30 years, over 53,000 children have benefited from solid organ transplantation.([@R1]) Advancements in organ procurement procedures, surgical techniques, anesthetics, post-operative management and refined immunosuppression protocols have drastically improved short-term survival; greater than 90% of pediatric solid organ transplant recipients are alive 1-year post transplant. There is now an increasing shift in focus on reducing morbidity from life-long immunosuppressive medications and optimizing long-term survival.

Infectious complications remain a major source of morbidity and mortality for all transplant recipients regardless of organ graft type.([@R2]-[@R4]) Pediatric transplant recipients are at heightened risk for infections compared to adult recipients, including VPIs, as children may lack previous immunity from natural exposure and may not have had time to finish their primary immunization series by the time of transplant.([@R5]-[@R7]) This article provides an overview on the incidence and impact of VPIs in the pediatric solid organ transplant population, and proposes policies and tools to improve immunization rates, decrease VPIs and improve long-term outcomes in this high-risk pediatric population.

Incidence of Vaccine-Preventable Infections in Pediatric Solid Organ Transplant Recipients {#S2}
==========================================================================================

VPIs (including influenza, pneumococcus, meningococcus, *Haemophilus influenzae*, human papillomavirus, varicella, pertussis, rotavirus, measles, mumps, Hepatitis A and Hepatitis B) are a common occurrence after pediatric solid organ transplantation.([@R8]-[@R17]) In a recent study of nearly 7,000 pediatric solid organ transplant recipients from 45 tertiary care centers across the United States, 1,092 (15.6%) were hospitalized with a VPI in the first five years post-transplant.([@R18]) The most common VPIs were influenza (40% of cases), rotavirus (19% of cases), varicella (11% of cases), pneumococcus (10% of cases) and respiratory syncytial virus (RSV) (10% of cases). The rates of hospitalization for these infections in the first year post transplant were much greater than the expected annual rates of hospitalization in the general pediatric population (influenza 3.0% of the transplant population vs 0.06% of the general pediatric population, rotavirus 2.6% of the transplant population vs 0.03% of the general pediatric population, pneumococcus 1% of the transplant population vs 0.5% of the general pediatric population and RSV 1.8% of the transplant population vs 0.3% of the general pediatric population). These statistics do not include those transplant recipients who had a VPI that was managed in the outpatient setting, which presumably would also occur at higher rates in pediatric transplant recipients compared to healthy children.

Morbidity, Mortality and Costs from Vaccine-Preventable Infections in Pediatric Solid Organ Transplant Recipients {#S3}
=================================================================================================================

VPIs result in significant morbidity, morbidity, graft injury and hospitalization costs after transplant.([@R8]-[@R17], [@R19]) In Feldman et al.'s study of over 7,000 children who received a solid organ transplant between 2004-2011, the overall case fatality rate for VPIs was 1.7%.([@R18]) The case-fatality rate for each individual VPI was significantly higher in the transplant population than in the general pediatric population. Pediatric transplant patients compared to the generic pediatric population had 53 times greater mortality rate from RSV, 17 times greater mortality rate from pneumococcus, 23 times greater mortality rate from rotavirus and 4 times greater mortality rate from influenza. Excluding infections that occurred during the initial transplant hospitalization during which every child would be intubated for the transplant surgery and then return to the intensive care unit (ICU) post-operatively, 8% of children with a VPI required mechanical ventilation and 17% required ICU-level care. Transplant hospitalizations complicated by a VPI were on average \$120,000 more expensive and 39 days longer than transplant hospitalizations not complicated by a VPI.

VPIs can also result in vaccine-preventable cancers (VPCs) which have associated morbidity, mortality and costs. In a cohort study of over 187,000 transplant recipients, 890 human papillomavirus related cancers were observed.([@R11]) Compared to the general population, transplant recipients had a 3-20 fold increased risk for vaginal, anal, vulvar and penile *in situ* cancers and a 2-7 fold increased risk for invasive cancers.

Increasing Rates of Vaccine Hesitancy, Non-Medical Vaccine Exemptions, and Vaccine Preventable Infections Across the United States {#S4}
==================================================================================================================================

Immunization is one of the most cost-effective ways of avoiding disease. It has been estimated that vaccination prevents approximately 42,000 early deaths and 20 million cases of disease, with net savings of \$13.5 billion in direct costs and \$68.8 billion in total societal costs, respectively.([@R20]) Despite the proven benefits of vaccination,([@R21]-[@R25]) vaccine hesitancy (the reluctance or refusal to vaccinate despite the availability of vaccines) continues to threaten progress made in tackling VPIs. According to data from the 2017 National Immunization Survey, the percentage of children less than 24 months of age who had received no vaccines at all had risen to 1.3%, up from 0.3% in the 2001 survey.([@R26]) A study recently published by Olive et al found an increase since 2009 in "philosophical-belief" non-medical vaccine exemptions in 12 of 18 states that allow "philosophical-belief" exemptions and describe hot spots of significantly lower vaccine rates in certain large urban and also rural areas.([@R27]) Likewise, for the third year in a row the Center for Diseases Control and Prevention observed a rising rate of exemptions from school vaccination amongst children entering kindergarten.([@R28]) The number of children who receive some vaccines but refuse or delay others is much higher than these statistics indicate.

Importantly, because under immunization and vaccine refusal tend to cluster geographically,([@R27], [@R29], [@R30]) vaccination rates in some areas may fall well below levels needed to maintain "herd immunity" for individual diseases, resulting in outbreaks.([@R21], [@R29], [@R31]) "Herd immunity" describes a concept where immunization of a significant portion of the population provides some degree of protection for those members of society who have not or cannot develop immunity (for example, people with allergies to vaccines, children who are too young to receive vaccines, or immunocompromised people who either cannot receive certain vaccines (such as live vaccines) or who cannot mount an immune response to vaccines). Vaccine refusal has been associated with outbreaks of multiple infections that are potentially vaccine-preventable including *Haemophilus influenzae* type b, ([@R32]) varicella, ([@R25]) pneumococcus, ([@R24]) pertussis ([@R33], [@R34]) and measles.([@R34], [@R35]) World Health Organization data shows a rise in the number of cases of measles in almost every region of the world, with 30% more cases in 2017 than 2016. In 2018, there were over 370 confirmed measles cases in the US, which is the second largest number since measles was eliminated in the US in 2000;([@R36]) in just the first four months of 2019, this number has already been exceeded. The recent outbreaks of measles in Washington, Minnesota, and New York state exemplify what happens when the vaccine rate is lower than required for herd immunity in geographic centers.

Under-Immunization of Solid Organ Transplant Candidates {#S5}
=======================================================

As is the case with the general population, immunizations are a minimally-invasive, cost-effective and safe approach to reducing the incidence of VPIs in children who are transplant candidates. Although immunizations will likely not prevent every case of VPI in the immunosuppressed transplant recipient, they can help decrease the incidence and severity of VPIs in this population. The Infectious Diseases Society of America (IDSA) and the American Society of Transplantation (AST) recommend that "solid organ transplant candidates receive all age-appropriate vaccines based on the Centers for Disease Control (CDC's) annual schedule for immunocompetent persons."([@R37], [@R38]) The North American Society for Gastroenterology, Hepatology and Nutrition (NASPGHAN), The American Association for the Study of Liver Diseases (AASLD) and the AST recommend in their joint practice guideline on evaluation of the pediatric patient for transplant that "completion of all age-appropriate vaccinations should occur prior to transplantation and ideally before the development of end-stage liver disease; and that children who have not completed the necessary vaccine schedule can receive vaccinations on an accelerated schedule."([@R39]) It is crucial for immunizations to be maximized pre-transplant as 1) vaccines are more immunogenic before immunosuppressive therapies are initiated post-transplant, 2) administration of vaccines pre-transplant increases the immunogenicity of vaccines post-transplant, and 3) live vaccines are currently not recommended for the majority of transplant recipients due to the risk of causing vaccine-strain disease in an immunocompromised host.([@R40], [@R41])

Despite these recommendations, and in spite of the fact that children with organ failure receive constant medical surveillance given their acutely ill status, the majority of transplant recipients are not up-to-date on age-appropriate immunizations at the time of transplant. In a recent study of over 300 pediatric liver transplant recipients from 34 North American centers, only 29% of children were completely up-to-date for age-appropriate immunizations using the CDC's standard immunization schedule and only 19% were up-to-date using the accelerated immunization schedule for transplant candidates.([@R42]) Under-immunization was a universal problem across all liver transplant recipients and was not associated with specific demographic or clinical factors. Live vaccines were particularly under-utilized amongst children aged 6-11 months, suggesting that practitioners may not be aware of the ability to accelerate live vaccines before a year of age in transplant candidates.

Ethics of Immunization in the Solid Organ Transplant Population -- Can and Should We Require That All Pediatric Transplant Candidates be Fully Immunized Before Receiving an Organ? {#S6}
===================================================================================================================================================================================

Currently, the decision about whether to offer transplantation to a child who is under-immunized is left to the discretion of each individual transplant center. In a survey of 73 North American pediatric hepatologists, 19% stated that their program lacked any written protocols regarding pre- and post-transplant immunization policies.([@R43]) In a separate survey of 114 medical directors, surgical directors and transplant coordinators from 138 pediatric heart, kidney and liver transplant programs in the United States (US), 39% of respondents reported that their program had encountered listing decisions involving a child whose parents or caregivers refused vaccination; however, only 4% reported that their program had a written policy regarding parental vaccine refusal before transplant.([@R44]) When given a hypothetical scenario about whether they would list such a child who was not fully vaccinated due to parental refusal, 47% of respondents stated that they would still list the child for transplant.

Given the growing mismatch between the number of people in need of an organ and the number of organs available, resulting in twenty deaths on the transplant waiting list each day,([@R45]) one must ask whether the United Network of Organ Sharing (UNOS) should institute a national policy requiring complete age-appropriate immunization for non-emergent transplants, rather than leaving this decision to individual centers. Such a policy would prevent a patient/family from "center shopping" to find a transplant center that doesn't require immunizations.

Additionally, institution of a national policy regarding immunization for non-emergent transplant candidates would uphold several important ethical goals including beneficence, utilitarianism, and justice.([@R46]) According to the principle of beneficence, there is a moral obligation to maximize well-being and minimize possible harms for an individual patient.([@R47]) Vaccines are potentially lifesaving for immunocompromised patients and should be treated as such.([@R46]) All transplant recipients receive immunosuppressive medications to prevent graft rejection, and therefore are at increased susceptibility for infection. Although vaccines cannot prevent all infectious complications, they decrease the probability of getting VPIs which are known to cause encephalitis, meningitis, pneumonitis, allograft rejection and death after transplant.([@R18], [@R19], [@R48]) According to the principle of utilitarianism, there is an obligation to consider the best ultimate outcome for society as a whole. With vaccines, this is where the concept of "herd immunity" or "community immunity" becomes important. Immunization not only directly protects the individual vaccinnee by reducing the chance of infection and possible complications; but also, indirectly benefits society by lowering the probability that non-immune members of society will come into contact with an infectious person and lowering the probability that the disease will circulate.([@R49], [@R50]) Finally, according to the principle of justice there should be fair, equitable and appropriate distribution of scarce resources. Despite advances in technology and efforts to increase organ donation awareness, there are more people in need of organs than there are organs available. If an under-immunized child loses a graft or dies post-transplant secondary to an infection that was potentially vaccine-preventable, the loss of that organ harms not only that child but every person who died on the waiting list because no organ was available.

A Call to Action for the Pediatric Community {#S7}
============================================

The barriers to vaccinating pediatric transplant candidates have not been well-studied, but similar to vaccination in the general population they are complex and will require a multi-pronged solution. In addition to consideration of stricter policies requiring immunizations for non-emergent transplant candidates, the pediatric community must come together to develop new multi-disciplinary practice guidelines to improve immunization rates for transplant candidates who are jointly cared for by primary care providers and subspecialists so that children don't fall through the cracks. These policies must establish that the standard of care is that all patients should be as up-to-date as possible on standard vaccines by the time of transplant. The guidelines should also provide guidance to centers on catch-up vaccination in under-immunized patients who are being evaluated for transplant, acceleration of live-virus vaccines before transplant, and circumstances under which live vaccines should be reconsidered post-transplant. Transplant centers need strong national policies to guide and support their local center policies on vaccines.

In addition to standard barriers to immunization faced by healthy children (parental concern about vaccine side effects, safety and pain; lack of access to health care; lack of insurance coverage; and moral or religious objections),([@R51]-[@R55]) transplant candidates face unique transplant-specific immunization barriers. These include divided care between multiple care-providers, acute medical problems that may overshadow preventative care, inaccurate provider knowledge about vaccinating patients in the pre-transplant period and division of the medical home between the primary care provider and subspecialist.([@R56]) In addition, some providers are still concerned about immunizations causing graft rejection,([@R57]) although this has been disproven by multiple studies.([@R58], [@R59]) Transplant centers may also face center-specific unique barriers and thus will need the resources (time, expertise, financial) to identify and understand their own barriers.

To overcome these barriers, novel tools are necessary to 1) educate subspecialists, primary care providers and allied health professionals about transplant-specific immunization guidelines, 2) provide data about vaccine safety and efficacy in the transplant population to help address and overcome potential vaccine fear or hesitancy, 3) improve communication among patients and their families and a medical team that consists of multiple care providers and 4) help create automated vaccine reminders.

Health information technology (IT) solutions have been demonstrated to facilitate patient-provider communication, increase adherence to medical regimens and improve outcomes in chronic illnesses.([@R60], [@R61]) Digital health tools on multiple technology platforms (mobile-phone, electronic medical record and web-based) have shown to be effective for immunization specific needs, including but not limited to creation of population-based immunization registries,([@R62]-[@R65]) implementing vaccine reminder/recall systems,([@R66]-[@R71]) providing education about vaccines for parents and providers,([@R72]) providing automated clinical decision support or "practice alerts",([@R73]-[@R76]) reducing missed vaccine opportunities and increasing immunization rates.([@R53], [@R54], [@R72], [@R77], [@R78]) Future cloud-based tools could be developed that are specifically tailored to the needs of the transplant population to provide 1) education about vaccine safety, efficacy and use pre- and post-transplant, 2) communication portals to facilitate sharing of information between patients and multiple providers, 3) a centrally located, easily accessible vaccine record and 4) automated vaccine reminders triggered from the accelerated schedule to assist with logistics of vaccine timing. In a recent qualitative study of 53 pediatric liver stakeholders, 94% believed that a health IT tool would be useful in increasing pre-transplant immunization rates.([@R56])

Conclusions {#S8}
===========

Immunizations are one of the most important public health interventions in history and are responsible for decreasing childhood morbidity and mortality from vaccine-preventable infections worldwide. Each year we invest \$1.2 billion dollars in pediatric solid organ transplants;([@R79]) however, we fail to protect our investment and the lives and health of our patients by ensuring that these immunosuppressed children are fully immunized. Unfortunately, the transplant population is not the only high-risk population of children who remain under-immunized, as under-immunization is also reported in children with lupus,([@R80]-[@R83]) inflammatory bowel disease,([@R84]-[@R87]) and rheumatoid arthritis.([@R88]) As a pediatric community we must come together to strengthen transplant immunization policies and utilize health IT tools to facilitate immunization delivery in a high-risk population that is jointly cared for by primary care providers and multiple subspecialists.
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